Medical Advocates
Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)
   
Main Page

New and Noteworthy
Product Information
Journal Citations
Conference Citations
Perinatal Data
Pediatric Data
Atripla
 

  
Tenofovir Main Page Main New/Newsworthy  Home Page      

This web page is best viewed by using INTERNET EXPLORER
Last Update:  February 20, 2018
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
February 2018
 
Perinatal Data
 
 
    Journal Papers, Abstracts, and Commentaries
 
  A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
 Samuel R, Paredes R, Parboosing R,  et al
 J Med Virol. 2015 May 4.
Abstract

FULL-TEXT ARTICLE
Is tenofovir/emtricitabine teratogenic?
Jibril M, Egunsola O.
Ther Adv Drug Saf. 2013 Jun;4(3):115-7.
Paper

Single-dose tenofovir and emtricitabine for reduction of viral resistance to
non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum
nevirapine for perinatal HIV prevention: an open-label randomised trial.
 Chi BH, Sinkala M, Mbewe F, et al
 Lancet. 2007 Nov 6;
 Abstract
Pediatric Data
     
    Journal Papers, Abstracts, and Commentaries
 
  Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.
 Falcon-Neyra L, Palladino C, Navarro Gómez ML, et al
Medicine (Baltimore). 2016 Jun;95(24):e3842.
Abstract

 

 

Tenofovir Main Page Main New/Newsworthy  Home Page      

Tenofovir Disoproxil Fumarate/Emtricitabine  (Truvada)
Main Page